The Only FDA-Approved Growth Hormone Peptide — And What It Actually Proved

Scroll through the world of growth hormone-related peptides and you'll find plenty of compounds with compelling mechanisms and thin human data. Tesamorelin is the exception, and it's worth understanding exactly what set it apart, because the distinction is about evidence quality, not just marketing.

Tesamorelin is a stabilized analog of GHRH — the signal your hypothalamus normally sends the pituitary to trigger growth hormone release. Rather than flooding the body with synthetic HGH directly, it works one step upstream, prompting the pituitary to release the body's own hormone, in its own natural pulsatile pattern.

What made Tesamorelin notable in trials was where the effect concentrated. It selectively reduced visceral fat — the deep, metabolically active fat wrapped around internal organs that carries outsized cardiometabolic risk — while largely sparing subcutaneous fat and preserving lean mass. That specificity is unusual; most fat-reduction interventions don't discriminate between fat compartments this cleanly.

The part that genuinely separates Tesamorelin from most of the peptide field is methodological, not mechanistic: it went through real randomized, placebo-controlled human trials, published in the New England Journal of Medicine, and earned FDA approval on that basis. Researchers have since followed the compound into related areas — liver fat, blood lipid profiles, and even cognitive measures — building out a broader evidence base beyond the original approval indication.

It's worth being precise about scope. The FDA approval covers a specific medical population (HIV-associated lipodystrophy), and the broader questions about wider applicability are still being actively studied rather than settled. But as a proof point for how far peptide research can actually go when it's run through the full gauntlet of controlled human trials, Tesamorelin stands out from a field where most compounds never make it past animal models.

Why this matters for tracking: visceral fat is a distinct, clinically meaningful compartment that a bathroom scale can't tell you anything about. If cardiometabolic risk is something you're actively managing, tracking waist-to-hip ratio or imaging-based visceral fat measures alongside lipid and insulin sensitivity markers gives you a far more accurate read than weight alone — and it's the specific thing this compound's trial data actually targeted.